Literature DB >> 22350626

Rapid sample size calculations for a defined likelihood ratio test-based power in mixed-effects models.

Camille Vong1, Martin Bergstrand, Joakim Nyberg, Mats O Karlsson.   

Abstract

Efficient power calculation methods have previously been suggested for Wald test-based inference in mixed-effects models but the only available alternative for Likelihood ratio test-based hypothesis testing has been to perform computer-intensive multiple simulations and re-estimations. The proposed Monte Carlo Mapped Power (MCMP) method is based on the use of the difference in individual objective function values (ΔiOFV) derived from a large dataset simulated from a full model and subsequently re-estimated with the full and reduced models. The ΔiOFV is sampled and summed (∑ΔiOFVs) for each study at each sample size of interest to study, and the percentage of ∑ΔiOFVs greater than the significance criterion is taken as the power. The power versus sample size relationship established via the MCMP method was compared to traditional assessment of model-based power for six different pharmacokinetic and pharmacodynamic models and designs. In each case, 1,000 simulated datasets were analysed with the full and reduced models. There was concordance in power between the traditional and MCMP methods such that for 90% power, the difference in required sample size was in most investigated cases less than 10%. The MCMP method was able to provide relevant power information for a representative pharmacometric model at less than 1% of the run-time of an SSE. The suggested MCMP method provides a fast and accurate prediction of the power and sample size relationship.

Entities:  

Mesh:

Year:  2012        PMID: 22350626      PMCID: PMC3326172          DOI: 10.1208/s12248-012-9327-8

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  35 in total

Review 1.  More efficient clinical trials through use of scientific model-based statistical tests.

Authors:  E Niclas Jonsson; Lewis B Sheiner
Journal:  Clin Pharmacol Ther       Date:  2002-12       Impact factor: 6.875

2.  Evaluation of hypothesis testing for comparing two populations using NONMEM analysis.

Authors:  D B White; C A Walawander; D Y Liu; T H Grasela
Journal:  J Pharmacokinet Biopharm       Date:  1992-06

3.  Statistical guide for clinical pharmacology & therapeutics.

Authors: 
Journal:  Clin Pharmacol Ther       Date:  2010-06-30       Impact factor: 6.875

4.  Design in nonlinear mixed effects models: optimization using the Fedorov-Wynn algorithm and power of the Wald test for binary covariates.

Authors:  Sylvie Retout; Emmanuelle Comets; Adeline Samson; France Mentré
Journal:  Stat Med       Date:  2007-12-10       Impact factor: 2.373

5.  Simultaneous versus sequential optimal design for pharmacokinetic-pharmacodynamic models with FO and FOCE considerations.

Authors:  J M McGree; J A Eccleston; S B Duffull
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-02-18       Impact factor: 2.745

6.  Application of GEE procedures for sample size calculations in repeated measures experiments.

Authors:  J Rochon
Journal:  Stat Med       Date:  1998-07-30       Impact factor: 2.373

7.  Balanced designs in longitudinal population pharmacokinetic studies.

Authors:  E I Ette; H Sun; T M Ludden
Journal:  J Clin Pharmacol       Date:  1998-05       Impact factor: 3.126

8.  Population pharmacokinetic/pharmacodynamic methodology and applications: a bibliography.

Authors:  L Yuh; S Beal; M Davidian; F Harrison; A Hester; K Kowalski; E Vonesh; R Wolfinger
Journal:  Biometrics       Date:  1994-06       Impact factor: 2.571

9.  The SAEM algorithm for group comparison tests in longitudinal data analysis based on non-linear mixed-effects model.

Authors:  Adeline Samson; Marc Lavielle; France Mentré
Journal:  Stat Med       Date:  2007-11-30       Impact factor: 2.373

10.  Intravenously administered digoxin in patients with acute atrial fibrillation: a population pharmacokinetic/pharmacodynamic analysis based on the Digitalis in Acute Atrial Fibrillation trial.

Authors:  Björn Hornestam; Markus Jerling; Mats O Karlsson; Peter Held
Journal:  Eur J Clin Pharmacol       Date:  2003-02-19       Impact factor: 2.953

View more
  25 in total

1.  Rapid sample size calculations for a defined likelihood ratio test-based power in mixed-effects models.

Authors:  Camille Vong; Martin Bergstrand; Joakim Nyberg; Mats O Karlsson
Journal:  AAPS J       Date:  2012-02-17       Impact factor: 4.009

2.  Model based design and analysis of phase II HIV-1 trials.

Authors:  Dinko Rekić; Daniel Röshammar; Ulrika S H Simonsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-07-11       Impact factor: 2.745

3.  Dose-response modelling of umeclidinium and fluticasone furoate/umeclidinium in asthma.

Authors:  Shuying Yang; Navin Goyal; Misba Beerahee; Roopa Trivedi; Laurie Lee; Steven Pascoe
Journal:  Eur J Clin Pharmacol       Date:  2015-07-16       Impact factor: 2.953

4.  Analysis of opioid consumption in clinical trials: a simulation based analysis of power of four approaches.

Authors:  Rasmus Vestergaard Juul; Joakim Nyberg; Mads Kreilgaard; Lona Louring Christrup; Ulrika S H Simonsson; Trine Meldgaard Lund
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-04-07       Impact factor: 2.745

5.  Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis.

Authors:  Lizanne de Kock; Sherwin K B Sy; Bernd Rosenkranz; Andreas H Diacon; Kim Prescott; Kenneth R Hernandez; Mingming Yu; Hartmut Derendorf; Peter R Donald
Journal:  Antimicrob Agents Chemother       Date:  2014-08-11       Impact factor: 5.191

6.  Statistical power calculations for mixed pharmacokinetic study designs using a population approach.

Authors:  Frank Kloprogge; Julie A Simpson; Nicholas P J Day; Nicholas J White; Joel Tarning
Journal:  AAPS J       Date:  2014-07-11       Impact factor: 4.009

7.  The power of modelling pulsatile profiles.

Authors:  Michiel J van Esdonk; Jasper Stevens
Journal:  J Pharmacokinet Pharmacodyn       Date:  2021-03-03       Impact factor: 2.745

8.  Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose.

Authors:  R J Keizer; M O Karlsson; A Hooker
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-06-26

9.  Comparisons of Analysis Methods for Proof-of-Concept Trials.

Authors:  K E Karlsson; C Vong; M Bergstrand; E N Jonsson; M O Karlsson
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-01-16

10.  A population pharmacokinetic model of piperaquine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Sudan.

Authors:  Richard M Hoglund; Ishag Adam; Warunee Hanpithakpong; Michael Ashton; Niklas Lindegardh; Nicholas P J Day; Nicholas J White; Francois Nosten; Joel Tarning
Journal:  Malar J       Date:  2012-11-29       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.